Esophageal cancer T3N2M0 belongs to stage III esophageal cancer, and its five-year survival rate is about 20%-30%.
Esophageal cancer is a malignant tumor disease originated from the epithelial cells of esophageal mucosa, and its etiology is still unclear, and it is considered to be related to heredity and stimulation of long-term adverse factors. Esophageal cancer T3N2M0 refers to the tumor tissue invading the esophageal fibrous membrane, accompanied by 3-6 regional lymph node metastasis, and no distant metastasis yet.
In this period, esophageal cancer is mainly treated by surgical resection of the lesion and lymph node dissection, supplemented by radiotherapy after surgery; those who are not suitable for surgery can be treated with radiotherapy and other methods to slow down the progress of the disease. After active treatment, the five-year survival rate of progressive esophageal cancer is about 20%-30%.
It is recommended that patients should consult the doctor in time and take active treatment to avoid delaying the condition.